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Plasma lipids and the progression of nephropathy in diabetes mellitus
type 11: Effect of ACE inhibitors. Ninety-four normotensive type II
diabetics with normal renal function and microalbuminuria were random-
ized to receive enalapril 10 mg/day or placebo and were followed for five
years. In the patients treated by enalapril plasma creatinine values and
albuminuria remained stable throughout the observation period. Their
plasma total cholesterol decreased from an initial value of 245 27 mg/dl
to mean study value of 236 29 mg/dl, and to a fifth year value of 232
27 mg/dl (P < 0.001). The changes in HDL cholesterol and triglyceride
values were nonsignificant. In the placebo group there was a significant
increase in albuminuria and a mean decline of 13% in reciprocal
creatinine values during the five years. Plasma total cholesterol increased
from an initial mean value of 246 24 to a mean study value of 252 25
mg/dl, and to a fifth year mean value of 259 32 mg/dl (P <0.001). There
was a significant correlation between both initial and mean plasma total
cholesterol values, and the decline in renal function and the rise in
albuminuria in the placebo treated patients. This correlation persisted
after stratification for blood pressure. Treatment with enalapril did not
eliminate these correlations. Cholesterol may be an additional risk factor
for diabetic nephropathy. ACE inhibitors may have a modest cholesterol
lowering effect in diabetic patients mediated, in part, through the decline
in albuminuria.
There is a growing body of evidence that hyperlipidetnia may
play a role in the progression of renal disease [1, 2]. Studies in
experimental animals have suggested a modest influence of
abnormal lipid metabolism on the formation of glomerular le-
sions, especially focal glomerular sclerosis [3, 4]. In association
with other factors like hypertension, diabetes or renal ablation,
the influence of hyperlipidemia on the decline in renal function
may become significant [5—8].
Renal disease is uncommon in patients with hyperlipidemia,
although lipid-related renal injury has been documented in some
rare genetic or metabolic disorders [9, 10]. Some retrospective
and uncontrolled data suggest that in diabetic nephropathy cho-
lesterol blood levels are important in conjunction with other
factors in the determination of the degree of progression of renal
damage. Mulec et al [11] found, in type I diabetics with nephrop-
athy, that the rate of decline in renal function was more than
threefold in patients with blood cholesterol levels higher than 270
mg/dl as compared to those with lower levels. Jerums et al [6]
found progressively increased serum concentrations of apopro-
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tein(a) in type II diabetics with nephropathy not related to mean
HbAIC levels. Lipid lowering agents (HMGC0A inhibitors) were
found to reduce proteinuria in patients with the nephrotic syn-
drome [12] and to some degree also in type I diabetics with
nephropathy [13]. There are no data, however, about the corre-
lation between plasma lipid levels and the progression of ne-
phropathy in type II diabetes and no prospective studies of
appreciable duration to permit an evaluation of the predictive
value of plasma cholesterol concentration on the course of
nephropathy.
We have followed prospectively, for five years, a group of 94
patients with diabetes mellitus type II. Initially they had mi-
croalbuminuria, normal renal function and normal blood pres-
sure. The correlations of the initial values and follow-up values of
plasma lipids with the progression of nephropathy are presented
in patients who received no specific treatment and in those treated
with an angiotensin-converting enzyme inhibitor.
Methods
One hundred eight normotensive patients with type II diabetes
mellitus were recruited during 1986. They were 34 to 49 years old
and had normal renal function and microalbumimuria of 30 to 300
mg/24 hr. The diagnostic criteria, exclusion criteria the follow-up
protocol and laboratory methods have been published elsewhere
[14]. In brief, each patient was followed every three to four
months for exactly five years. Fasting blood sugar, serum creati-
nine and 24 hour albuminuria were determined at each visit. Total
cholesterol, HDL and triglyceride values were determined at
every second visit. Sitting blood pressure was taken twice at each
visit. Any rise in blood pressure beyond 140/90 mm Hg was
controlled with long acting nifedipine. Mean blood pressure,
defined as diastolic pressure plus one third of the pulse pressure,
was calculated for each visit. Total cholesterol and triglycerides
were determined by the colorimetric enzymatic method of Allain
et a! [15] using the Hitachi 747. HDL cholesterol was determined
after a phosphotungstic acid and magnesium chloride precipita-
tion step. The values of LDL cholesterol were calculated by
Friedenwald's formula [16]. The patients were randomized to
receive either enalapril, 10 mg/day or placebo. Eight patients left
the study during the first year and three were lost to follow-up. Six
patients developed side effects, mainly intolerable cough (4 were
on enalapril and 2 on placebo), and were excluded from the study.
The study therefore comprised 94 patients, 49 of whom received
enalapril and 45 placebo.
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Table 1. Baseline, and final data in 94 type II diabetic patients
Enalapril Placebo
Initial Final Initial Final
No. of patients 49 49 45 45
Mean age years 43.5 3 48.5 3.5 44.8 3.5 49.8 3.8
Mean blood 99 2 100 3.2 97 3 102 3.4
pressure
mm Hg
BMI kg/rn2 23.7 1.3 24.3 1.6 25.1 1.2 26.2 2.1
GHb % 10.4 2.1 10.6 2.4 10.4 2.6 10.4 2.7
Serum creatinine 1.2 0.07 1.23 0.1 1.16 0.09 1.32 0.12
mg/dl
Reciprocal 0.93 0.053 0.92 0.075 0.98 0.076 0.86 0.078
creatinine
Albuminuria 143 64 140 104 123 58 310 167
mg124 hr
Data are mean SD.
Abbreviations are: BMI, body mass index; GHb, glycosylated hemoglo-
bin.
The conversion factor for creatinine is mg/dl X 88 = mmol/liter.
Statistical analysis
Pooled variance Student's t-test for independent groups as well
as one way analysis of variance were used to test the hypothesis of
no difference between the means of the initial parameters in the
two groups. One between-group factor and one repeated-mea-
sures factor were used in analysis of variance, of individual patient
data in order to compare the various follow-up measurements
between the two groups, and within each group. The rate of
decrease of reciprocal creatinine and the rate of increase of
albuminuria were calculated by regression analysis.
Multiple regression analysis was performed with the percentage
decline in reciprocal creatinine (Cr) as the dependent variable
and mean glycosylated hemoglobin, mean blood pressure, initial
and mean plasma total cholesterol values as the independent
variables. Least squares linear regression equation was used to
test the correlation between the initial values of plasma choles-
terol and daily albuminuria.
Pearson correlation coefficients and partial correlations were
computed between the change in reciprocal creatinine, change in
total cholesterol and change in albuminuria.
Data were stored on the Quatro-pro software and analyzed by
the SPSS/PC system.
Results
The patient characteristics at baseline and at the end of the
study are listed in Table 1. The initial values of plasma lipids as
well as the study mean values and the corresponding values at the
end of the study are presented in Table 2. There was no
statistically significant difference between the baseline parameters
of the placebo and the enalapril groups. During the follow-up
period there was a gradual but modest rise in plasma total and
LDL cholesterol values in the placebo treated patients versus an
equally modest but clear decline in those values in the enalapril
treated patients. There was no change in plasma values of HDL in
either group; however, due to the changes in opposite directions
in the values of LDL, the LDLIHDL ratio differed significantly
between the placebo and the enalapril treated groups.
There was a modest decline in the blood levels of triglycerides
in both groups. The individual patterns, however, were inconsis-
tent.
In the placebo group there was a mean decline of 13% in
reciprocal creatinine values during the five years of the study. The
degree of the subsequent decline in renal function (ACr) could be
predicted by the initial total cholesterol value (r 0.783, P <
0.001), by the initial mean blood pressure value (r = 0.832, P <
0.001), by the value of initial albuminuria (r = 0.720, P < 0.01),
but not by age (r = 0.210) nor by the initial value of glycosylated
hemoglobin (r = 0.014), or HDL cholesterol (r —0.160). There
was also a significant correlation between the progression of renal
impairment and the mean study values of plasma total cholesterol
(r = 0.817, P < 0.001), of mean blood pressure (r = 0.817, P <
0.001), but no correlation with the study mean glycosylated
hemoglobin values (r = 0.120), or mean HDL values (r =
—0.180).
In the enalapril treated group there was only a marginal decline
in renal function (5 year zCr of 1%). Nevertheless, in each case
the initial values of albuminuria (r 0.860, P < 0.001), of plasma
total cholesterol (r = 0.735,P < 0.001), of mean blood pressure (r
= 0.759, P < 0.001), but not of age (r = 0.160) nor of glycosylated
hemoglobin (r = 0.140) or HDL cholesterol (r = —0.097) could
predict the subsequent evolution of renal function. There was,
also, a close correlation between the study mean values of plasma
total cholesterol and mean blood pressure and the individual Cr
(r = 0.811 and 0.782, respectively, P < 0.001). There was no
correlation between Cr and the mean study values of glycosy-
lated hemoglobin (r = 0.141). There was a borderline negative
correlation between zCr and the mean values of HDL cholesterol
(r =
—0.327, P < 0.05).
In the placebo group patients there was a significant correlation
between ACr and the increase in albuminuria (Alb) (r = 0.637,
P < 0.001). This association was insignificant in the enalapril
treated patients (P = 0.08).
There was a significant correlation between the initial values of
total cholesterol and albuminuria (r = 0.681, P < 0.001). When
the degree of increase in albuminuria was considered as a
parameter of renal deterioration, the predicive values of the initial
total cholesterol and blood pressure were highly significant. There
was also a significant correlation between Alb and the mean
study values of mean blood pressure and total cholesterol. The
correlations of these parameters with the change in albuminuria
are outlined in Table 3.
In the placebo group, the correlation between the change over
time in plasma levels of total cholesterol (iChol) and Cr was r
=
—0.122 (NS). The partial correlation free of the impact of z.Alb
was very similar, r = —0.104 (NS). By contrast, in the enalapril
treated patients the correlation between zChol and zCr was r =
—0.292 (P = 0.04), but, when controlled for AA1b it was reduced
to r = 0.010 (NS).
Discussion
The data of the present study have to be analyzed in view of two
basic questions. First, does a correlation exist between plasma
lipid levels and the progression of diabetic nephropathy, and
second, does angiotensin-converting enzyme inhibition have an
influence on plasma lipid levels. It seems that, with proper
caution, both these questions may be answered positively. How-
ever, our data cannot be interpreted as indicating a causative role
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Table 2. Initial, mean and final plasma values of total cholesterol (T. chol), LDL and HDL cholesterol and triglycerides (T.G.) in the placebo and
enalapril treated groups
Placebo (45 patients) Enalapril (49 patients)
Initial Mean FinalParameter Initial Mean Final
T. chol 246 24 253 25 259 32 245 27 236 29 232 27
LDL 163 17 170 17 176 21 162 19 156 20C 151 22
HDL 42 3.4 42 3.3 43 3.6 42 3.8 42 3.7 42 3.8
LDL/HDL 3.92 0,35 4.05 0.41 4.09 0.39 3.85 0.37 3.71 0.35" 3.6 036b
T.G. 201 64 192 56 189 54 197 58 183.8 49" 180 43"
Significance was tested by paired t-tests. Values are mgfdl SD.
The conversion factor for cholesterol is mg/dI X 0.02586 = mmollliter.
Significance of difference, placebo vs. enalapril.
ap < 0.001
bp <0.01
Table 3. Correlation between the progress of 24 hour values of
albuminuria (iAlb) over a 5 year period and the initial and mean study
values of mean blood pressure (BP) plasma total cholesterol, (T. chol)
and HDL cholesterol in 94 patients with diabetes mellitus type II
Placebo (45 patients) Enalapril (49 patients)
Partial Partial
correlation correlation
Correlation controlling Correlation controlling
Parameters with i.Alb for BP with Alb for BP
Initial BP 0.560a 0.507a
Mean study BP
Initial T. chol
0.670a
0.617a 0.455"
0.587a
0.584a 0392b
Mean study T. 0.658a 0.422" 0.651C 0.415"
chol
Initial HDL
C < 0.001
bp <0.01
C Not significant
of hyperlipidemia in the pathogenesis or progression of diabetic
renal disease.
There was a significant positive correlation between total
cholesterol and both the decline in renal function and the rise in
albuminuria over a five year period in the placebo as well as in the
enalapril treated patients. These correlations hold with both the
initial and the mean study values. They also remained significant
when the influence of blood pressure was neutralized. No cone-
lation was found, however, between the renal outcome and the
other parameters including HDL cholesterol, glycosylated hemo-
globin or age.
Hypercholesterolemia is also, therefore, an independent risk
factor for subsequent worsening of nephropathy in diabetes
mellitus type II. The initial levels of plasma cholesterol closely
correlated with both the initial albuminuria and the subsequent
increase in urinary albumin excretion. This association may
strengthen the assumption that hyperlipidemia is indeed a risk
factor for diabetic nephropathy. Alternatively, however, the ele-
vated lipid levels might have been secondary to the urinary loss of
albumin.
In the placebo group patients the correlation between the
change over time in plasma cholesterol levels and the change in
reciprocal creatinine was not altered when controlled for the
influence of the change in albuminuria. By contrast, neutralization
of the effect of albuminuria in the enalapril treated patients
eliminated the correlation between the change in lipids and renal
function. Thus the decline in cholesterol in the enalapril treated
patients may be due, in part, to the drop in albuminuria. The
reverse, however, may also be true. There is sporadic evidence
that lowering plasma cholesterol may reduce proteinuria [12, 13,
17].
An association between plasma cholesterol levels and progres-
sion of diabetic nephropathy was reported in patients with diabe-
tes mellitus type I [11] and also in nondiabetic patients with
proteinuria [18]. In patients with type II disease and without
proteinuria Silveiro, Friedman and Gross [19] found a positive
correlation between plasma cholesterol levels and glomerular
hyperfiltration. By contrast, Jerums and colleagues [6] found no
difference in plasma cholesterol levels of type II diabetics who did
or did not show progression of albuminuria over an 11 year
observation period. Their series comprised only 14 patients with
type II disease who showed progressive albuminuria. Also, Has-
slacher et al [5], in a five year observational study of 94 patients
with type II diabetes found a positive correlation between the
decline of kidney function and triglycerides, but not cholesterol
blood levels. They did, however, find the body mass index to be an
independent risk factor for the progression of nephropathy.
In an extensive review on hyperlipidemia and progressive renal
disease, Keane et al [2] point out that the incidence of renal
disease in patients with the common forms of hyperlipidemia is
probably quite low. They also conclude that plasma lipids may
become risk factors only when other significant risk factors
coexist. Diabetes mellitus may be a good example of such a
coexistence.
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